Affiliation:
1. University of Cologne Department of Chemistry Greinstraße 4 50939 Cologne Germany
2. Prosion Therapeutics GmbH Luxemburger Str. 90 50939 Köln Germany
3. Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) Robert-Rössle-Straße 10 13125 Berlin Germany
Abstract
AbstractUsing a set of conformationally restricted Proline‐derived Modules (ProMs), our group has recently succeeded in developing inhibitors for the enabled/vasodilator‐stimulated phosphoprotein homology 1 (EVH1) domain, which is a key mediator of cell migration and plays an important role in tumor metastasis. While these (formally) pentapeptidic compounds show nanomolecular binding affinities towards EVH1, their drug‐like properties and cell permeability need to be further optimized before they can be clinically tested as therapeutic agents against metastasis. In this study, we sought to improve these properties by removing the C‐terminal carboxylic acid function of our peptoids, either by late‐stage decarboxylation or by direct synthesis. For late‐stage decarboxylation of ProM‐like systems, a method for reductive halo decarboxylation was optimized and applied to several proline‐derived substrates. In this way, a series of new decarboxy ProMs suitable as building blocks for decarboxy EVH1 inhibitors were obtained. In addition, we incorporated decarboxy‐ProM‐1 into the pentapeptide‐like compound Ac[2ClF][ProM‐2][Decarb‐ProM‐1], which showed similar affinity towards EVH1 as the methyl ester derivative (Ac[2Cl‐F][ProM‐2][ProM1]OMe). However, despite better calculated drug‐like properties, this compound did not inhibit chemotaxis in a cellular assay.
Funder
Deutsche Forschungsgemeinschaft